BDX

Dividend Kings have earned their reputation by raising their payouts for at least 50 consecutive years, an accomplishment that requires navigating recessions, inflationary periods, rising interest rates, and numerous market cycles without breaking their streaks. Still, an exceptional dividend history doesn't automatically make a stock a buy at any given price. Earnings growth, valuation, and the direction of analyst estimates remain important considerations, particularly after quarterly results give Wall Street a fresh look at a business. Four Dividend Kings — Becton, Dickinson and Company BDX), Consolidated Edison ED), Emerson Electric EMR), and Parker-Hannifin PH) — reported earnings last week. Medical technology giant Becton, Dickinson and Company delivered better-than-expected results for its fiscal third quarter, with adjusted earnings of $3.23 per share topping estimates of $3.14 despite dipping from Q3 EPS of $3.68 a year ago following the separation of its Biosciences and Diagnostic Solutions operations. Revenue reached roughly $5 billion, down 9% from the prior-year period but topping expectations of $4.89 billion. That said, growth from its continuing businesses was broad-based. Medical Essentials revenue increased 4%, Connected Care rose 5%, BioPharma Systems advanced 6%, and BD Interventional climbed 6% on a reported basis. Cash generation was another bright spot, with year-to-date cash flow from continuing operations increasing by 33% to $2.1 billion and free cash flow increased over 44% to $1.7 billion. Management also tightened its fiscal 2026 adjusted EPS outlook to $12.62-$12.72, compared with its previous $12.52-$12.72 range, effectively raising the midpoint. The updated EPS range calls for 6-7% growth for the continuing business, although FY25 EPS came in at $14.40 last year before the separation of its Biosciences and Diagnostics operations. When accounting for the spin-off, full-year revenue growth is expected at low single digits from a continuing revenue base of $18.54 billion last year. The quarter wasn't flawless as gross and operating margins faced pressure while BD works through a significant portfolio transformation. Verdict: For investors, the appeal centers on a durable medical-technology franchise, improving cash generation and a long record of dividend growth. Yet a Zacks Rank #3 (Hold) suggests analysts' earnings revisions aren't currently strong enough to signal a more aggressive entry point, even with BDX shares having the cheapest forward P/E multiple on the list at 14X. Consolidated Edison provided the defensive flavor investors typically expect from a Dividend King while also delivering a sizable earnings beat. Second-quarter adjusted earnings came in at 83 cents per share, comfortably ahead of expectations of $0.74 and up from Q2 EPS of $0.67 a year earlier. Revenue increased 13% to $4.06 billion and easily topped Q2 estimates of $3.74 billion by 8%. The growth was supported by higher electric and gas rate bases, with Con Edison’s operating income surging 55% YoY to $552 million. Electric revenue rose 13% to $3.14 billion, gas revenue advanced 14% to $811 million, and steam revenue increased 11% to $118 million. Those gains helped offset higher purchased-power and fuel costs. Looking ahead, Con Edison reaffirmed its FY26 adjusted EPS guidance of $6.00-$6.20 (+5% growth). The utility provider also has an enormous investment program ahead, with nearly $38 billion in planned capital expenditures from 2026 through 2030. That spending should support rate-base growth over time, but utilities generally lack the explosive earnings potential found in more economically sensitive industrial businesses. Interest rates and valuation can also have an outsized influence on utility stocks because income-oriented investors frequently compare their yields with fixed-income alternatives. Verdict: ED remains attractive for investors prioritizing dividend reliability and defensive exposure, and its latest earnings beat reinforces the stability of Con Edison’s underlying business. However, the current Zacks Rank #3 (Hold) suggests the near-term earnings outlook is balanced rather than signaling a particularly compelling buying opportunity, even with ED shares trading at a very reasonable 17X foward earnings multiple. Among these four Dividend Kings, Emerson Electric produced one of the more impressive combinations of growth, margin expansion, and improving guidance. Reporting results for its fiscal third quarter, Emerson’s Q3 adjusted EPS increased over 12% to $1.71 and edged expectations of $1.68, while revenue climbed 7% YoY to $4.87 billion and topped estimates of $4.79 billion. Underlying sales advanced 6%, and underlying orders rose 7%, pointing to healthy demand across the automation specialist's portfolio. Software & Systems was particularly strong, posting an 11% sales increase, while Test & Measurement sales jumped 23%. Emerson also benefited from demand across power, aerospace and defense, liquefied natural gas and other longer-cycle markets. Backlog excluding its Aspen Tech asset manager software business increased 7% to $8.2 billion. Profitability added another positive element. Adjusted segment EBITA margin expanded 140 basis points to 28.5%, while Q3 operating cash flow jumped 34% and free cash flow rose 36%. Those results prompted management to raise its fiscal 2026 outlook. Net sales are now projected to grow approximately 5%, which would equate to around $19 billion, with underlying sales growth of around 3.5%. Full-year adjusted EPS is expected to be around $6.55 (9% growth), and Emerson anticipates generating approximately $3.6 billion in free cash flow. Roughly $2.2 billion is slated to be returned to shareholders through about $1 billion of repurchases and $1.2 billion of dividends. Verdict: Hold with a Bullish lean. While EMR currently lands a Zacks Rank #3 (Hold) as well, Emerson's operating trends look stronger, and it wouldn’t be surprising if a buy rating is on the way if analysts start to raise their earnings estimates in accordance with the company’s raised guidance. Rising orders, expanding margins, and increased guidance make EMR worth watching closely at a reasonable 25X forward P/E, particularly if upward earnings estimate revisions strengthen enough to support a higher Zacks Rank. As a global diversified manufacturer of motion and control technologies and systems, Parker-Hannifin arguably posted the strongest headline numbers of the four. PH’s fiscal fourth-quarter adjusted earnings surged 20% to $9.27 per share, easily topping EPS expectations of $8.29 by nearly 12%. Revenue increased roughly 10% to $5.75 billion, exceeding estimates of $5.6 billion, with organic sales growing 8%. Perhaps even more encouraging for future demand, was that orders soared 19% YoY. Strength came from both major operating businesses. Diversified Industrial sales increased 8%, while Aerospace Systems benefited from robust demand. For the full fiscal year, PH’s adjusted earnings advanced over 18% to $32.31 per share, and annual sales increased more than 8% to $21.5 billion. The company's profitability remains another major strength. Adjusted total segment operating income increased over 14%, and the corresponding margin expanded 110 basis points to 28%. Cash generation was also robust, with FY26 operating cash flow reaching $4.36 billion. It’s also worth noting that PH’s long-term debt fell to $6.77 billion from $7.49 billion a year earlier. For FY27, management expects both net sales and organic sales growth to be between 5.5%-8.5%, an adjusted segment operating margin of 27.5%-27.9%, and adjusted EPS of $34.25-$35.25 (+6% growth). Importantly, that guidance excludes the pending Filtration Group and CIRCOR Commercial and Defense Aerospace acquisitions. Verdict: Hold, with a bullish lean. PH's earnings beat, 19% order growth, and impressive margins make its fundamental story difficult to ignore. The primary question isn't the quality of the business but whether its current P/E valuation of 30X and earnings revisions provide enough upside to justify chasing shares immediately after their run, with PH stock spiking 8% this month. BDX, ED, EMR and PH stock have something very few publicly traded businesses can claim: dividend-growth records stretching across half a century or more. Their latest earnings reports also show that these mature businesses aren't relying solely on their dividend histories to attract investors. Becton Dickinson delivered broad-based revenue growth and stronger cash generation while lifting the midpoint of its earnings outlook. Consolidated Edison topped expectations and has a massive capital-investment program supporting its long-term rate base. Emerson Electric paired higher orders with margin expansion and raised guidance. Parker-Hannifin, meanwhile, produced double-digit earnings growth, a sharp increase in orders and another year of strong cash generation. The catch is that great businesses don't always equal great entry points for stocks. With all four stocks currently carrying a Zacks Rank #3 (Hold), the near-term earnings revision picture doesn't provide a clear enough catalyst to warrant an outright Buy rating and the plausibility of significant short-term upside. That doesn't make these Dividend Kings stocks to sell, either. Their durable businesses, shareholder-friendly capital allocation and decades-long dividend records make them compelling names to keep on investors' watchlists. For now, holding existing positions may be the most appropriate approach, while prospective buyers can watch for more favorable valuations or stronger upward earnings estimate revisions. Among the four, Emerson and Parker-Hannifin appear particularly intriguing following their strong operating results, and either could become more attractive should analyst revisions turn increasingly positive. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Emerson Electric Co. (EMR) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report Parker-Hannifin Corporation (PH) : Free Stock Analysis Report Consolidated Edison Inc (ED) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

This article first appeared on GuruFocus. Revenue: $5 billion, up 4.4% on an FX-neutral basis. Adjusted Operating Margin: 24.9%, down 130 basis points versus the prior year. Adjusted Gross Margin: 54.3%, down 100 basis points versus the prior year. Adjusted EPS: $3.23, up 4.9%. Free Cash Flow: $1.7 billion year to date, an increase of 45% versus the prior year. Segment Performance: Medical Essentials grew 3.2%, Connected Care grew 4.4%, BioPharma Systems grew 5.2%, and Interventional grew 5.5%. Guidance: Full-year revenue growth expected toward the high end of the low single-digit FX-neutral range; adjusted EPS guidance raised to $12.62 to $12.72. Warning! GuruFocus has detected 7 Warning Sign with BDX. Is BDX fairly valued? Test your thesis with our free DCF calculator. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Revenue of $5 billion grew 4.4% on an FX-neutral basis, exceeding expectations with broad-based growth across the portfolio. Key growth platforms delivered strong performance, including double-digit growth in biologic drug delivery, advanced patient monitoring, PureWick, and advanced tissue regeneration. Adjusted EPS of $3.23 increased 4.9% year-over-year, beating expectations and leading to a raised full-year EPS guidance midpoint. BD Excellence initiatives drove approximately 8% gross productivity in plants, with service levels above 90% and back orders at record lows. Free cash flow improved significantly, up 45% year-to-date to $1.7 billion, supporting capital returns and investment in growth. Commercial investments are yielding results, contributing 100-150 basis points to APM growth and driving share gains in Alaris and other platforms. Innovation pipeline is robust with new product launches like Liverty TIPS Stent Graft and Elyra Thulium Fiber Laser, expanding into high-growth markets. BioPharma Systems grew 5.2% despite vaccine headwinds, with strong GLP-1 momentum and approximately 100 signed agreements for novel and biosimilar programs. The company raised its full-year revenue growth outlook to the high end of the low single-digit range, reflecting confidence in continued momentum. China exposure is reduced to only 4% of New BD revenue, mitigating future market volatility risks. Adjusted operating margin declined 130 basis points year-over-year to 24.9%, impacted by tariffs and increased investments. Tariffs had an approximately 110 basis point negative impact on margins, with ongoing uncertainty around trade policies. Alaris capital sales faced a difficult prior-year comparison, creating a 200 basis point headwind to revenue growth in fiscal 2027. Vaccine demand in China remained weak, though stabilizing, with continued pressure on BioPharma Systems growth. China market dynamics continue to pose challenges, particularly in Interventional and Medical Essentials segments. The company expects a sequential deceleration in Q4 revenue growth due to Alaris comps, with growth slowing to approximately 2.5%. Fiscal 2027 revenue growth is expected to be low single-digit, with Alaris remediation end creating a 200 basis point headwind. Oil price volatility and resin costs present potential COGS headwinds, requiring proactive pricing actions to offset. The company faces a modest EPS leverage outlook for fiscal 2027, with limited margin expansion expected due to Alaris flow-through and investments. Management noted a conservative posture for fiscal 2027, with no formal guidance provided yet, creating uncertainty for investors. Q: The quarter showed strong momentum across many businesses, with 90% of the portfolio delivering high single-digit growth. Was there anything onetime in the results, and how much of this strength carries into fiscal 2027? A: Tom Polen, Chairman, CEO and President, stated that the growth was broad-based and driven by the company's key growth platforms, which are beginning to pay off as New BD. He highlighted double-digit growth in four platforms, including biologics (specifically GLP-1s), pharmacy robotics (Rowa), and advanced patient monitoring (APM). The company is reallocating a disproportionate amount of R&D into these growth vectors, which not only accelerate revenue but also provide favorable mix benefits to fuel margin expansion. Q: Given the strength in the quarter, could fiscal 2027 revenue growth be closer to the high end of low single digits? What are the puts and takes for the P&L, and can you grow operating margins next year? A: CFO Vitor Roque provided the fiscal 2027 framework, reiterating the expectation for low single-digit revenue growth. This is due to the 200 basis point headwind from the Alaris remediation ending in fiscal 2026. He noted that a good starting point for earnings is modest leverage on that revenue baseline, supported by pricing actions, productivity gains from BD Excellence, and capital allocation strategy. Formal guidance will be provided on the November call. Q: How much of the strong performance is due to changes in the commercial approach versus innovation platforms coming through? A: CEO Tom Polen explained it is a combination of both. He detailed the "Excellence Unleashed" strategy, which includes appointing the company's first Chief Revenue Officer, changing sales rep compensation, deploying AI tools, and reallocating commercial headcount to high-growth areas. He cited a $35 million incremental investment that grew the APM sales team by 15%, contributing 100 to 150 basis points to APM's growth, and a similar investment in the PI sales team. This is complemented by a shift in the innovation portfolio toward high-growth sectors like connected care and chronic disease treatment. Q: Can you comment on the broader hospital utilization and CapEx environment, given concerns in the market? A: CEO Tom Polen stated that BD sees solid utilization across its portfolio, acting as a bellwether for the industry. He cited strong US performance in MDS (up 6%) and specimen management (up 14%), driven by broad underlying utilization and share gains. He noted an internal metric showing an uptick in tube utilization versus needle utilization, indicating more diagnostic testing is being done per patient, which he views as a positive sign for overall health care consumption. Q: What are the trends and visibility on the 10% of the portfolio that is weighing on growth, specifically Alaris, China, and vaccines? A: CEO Tom Polen provided updates on the three known headwinds. For vaccines, he sees positive signs of stabilization and does not expect a repeat of the current headwind level in fiscal 2027. For China, he noted it is now a much smaller part of New BD (down to 4% of revenue) and will become less significant. For Alaris, he reiterated that the defined headwind will end in fiscal 2027, after which the company expects to return to its mid-single-digit growth algorithm. Q: How do you define "modest EPS leverage" for fiscal 2027, and what are the key product drivers over the next 12 to 18 months? A: CFO Vitor Roque clarified that "modest leverage" is an EPS starting assumption off the low single-digit revenue baseline, reflecting the Alaris flow-through and a dynamic environment. The company plans to offset this with pricing actions, mix favorability, and BD Excellence productivity. CEO Tom Polen highlighted product drivers including continued momentum in APM, new launches in tissue regeneration, pharmacy automation, biologics (with 100 GLP-1 agreements signed), and the Pyxis Pro launch in Connected Care. He also mentioned upcoming innovations to be unveiled at the Investor Day. Q: The guidance implies a step-down in Q4 growth to about 2.5%. Is that conservatism, and what are the assumptions on inflation and headwinds for next year? A: CFO Vitor Roque explained the Q4 step-down is due to the Alaris comp dynamics, with the headwind increasing from 100 basis points in Q3 to 200 basis points in Q4. He emphasized the underlying momentum remains strong. CEO Tom Polen addressed the macro environment, noting that resin and molded plastic components represent about 5% of COGS. The company is taking a conservative posture and has already implemented pricing actions to offset potential higher input costs, preferring to assume higher costs and be positively surprised if they improve. Q: How much more runway is there for productivity enhancement and margin expansion, and is a 30% operating margin by 2030 too ambitious? A: CEO Tom Polen outlined the multiyear road map for margin expansion, driven by revenue growth, positive mix from growth platforms, and BD Excellence. He noted the company has gone from 50 Kaizens a year to over 2,000, delivering over 500 basis points of margin expansion. He highlighted ongoing opportunities in OEE, material changes, procurement savings, and the application of AI to drive efficiency and cash flow. While he did not provide a specific long-term target, he confirmed an Analyst Day date will be shared soon to discuss long-term targets. Q: Can you provide more detail on the margin impact from the Alaris capital comp starting in Q4 and through fiscal 2027, and how you plan to offset it? A: CFO Vitor Roque stated the company has a clear pathway to deliver Q4 margin enhancements sequentially, despite the Alaris revenue decline, due to productivity gains already driven during the year. For fiscal 2027, the Alaris pressure is simply a natural drop-through of lower revenue to the bottom line. The company is actively mitigating this through pricing actions, investments in high-margin growth areas, and BD Excellence productivity, which are factored into the "modest EPS leverage" starting assumption. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Interested in Becton, Dickinson and Company? Here are five stocks we like better. Strong Q3 performance: Becton, Dickinson and Company reported $5 billion in fiscal 2026 third-quarter revenue, up 4.4% on an FX-neutral basis, while adjusted EPS increased 4.9% to $3.23. The company raised its full-year adjusted EPS outlook midpoint to $12.62–$12.72. Growth led by key platforms: Double-digit gains in biologic drug delivery, advanced patient monitoring, PureWick, advanced tissue regeneration and peripheral vascular disease supported broad-based results, with BD also expanding its GLP-1 partnerships and product offerings. Cash flow improved despite margin pressure: Year-to-date free cash flow rose 45% to $1.7 billion, although tariffs and commercial and R&D investments reduced adjusted operating margin to 24.9%. BD expects fiscal 2026 revenue growth near the high end of its low-single-digit range and approximately 25% adjusted operating margin. 3 Dividend Kings That Earn Their Crown Every Quarter Becton, Dickinson and Company (NYSE:BDX) reported third-quarter fiscal 2026 revenue of $5 billion, up 4.4% on an FX-neutral basis, as growth across its key platforms and operational productivity helped results exceed the company’s expectations. Chairman, Chief Executive Officer and President Tom Polen said the quarter was BD’s first full period operating as a focused medical technology company following the separation of its life sciences business. More than 90% of the portfolio delivered high-single-digit growth, he said, while several platforms posted double-digit gains. → Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs Adjusted operating margin was 24.9%, while adjusted diluted earnings per share rose 4.9% to $3.23. The company raised the midpoint of its full-year adjusted EPS outlook and now expects earnings of $12.62 to $12.72 per share. BD cited double-digit growth in biologic drug delivery, advanced patient monitoring, PureWick and advanced tissue regeneration. The company also reported strong performance in peripheral vascular disease and Rowa pharmacy automation. → 4 Oil and Gas ETF Plays as Prices Stay Sky-High Healthcare Stocks With at Least 30 Years of Dividend Increases Executive Vice President and Chief Financial Officer Vitor Roque said Medical Essentials revenue grew 3.2%, with strong U.S. performance in medication delivery solutions supported by share gains in vascular access management and utilization recovery following last year’s fluid shortage. Specimen management delivered high-single-digit growth, driven by share gains in the BD Vacutainer portfolio, improved supply and demand from customers working through competitor back orders. Connected Care revenue rose 4.4%, led by double-digit growth in advanced patient monitoring and continued strength in consumables. Medication management solutions grew at a low-single-digit rate, supported by double-digit dispensing growth and Rowa pharmacy automation, though results were partly offset by a difficult comparison in Alaris capital sales. → Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is Falling BioPharma Systems revenue increased 5.2%, driven by double-digit biologics growth led by GLP-1 programs. Excluding vaccines, the segment grew in the mid-teens, Roque said. Interventional revenue rose 5.5%, with growth in oncology and peripheral vascular disease, while the urology and critical care business benefited from continued double-digit PureWick growth. Surgery was supported by double-digit gains in infection prevention and advanced tissue regeneration. Polen said BD has signed approximately 100 agreements across novel and biosimilar GLP-1 programs. He also highlighted a collaboration with Brazilian pharmaceutical company EMS to launch a semaglutide therapy using BD’s Vystra injection pen. Management attributed part of its growth to commercial investments and a reallocation of sales resources toward higher-growth categories. Polen said investments in advanced patient monitoring contributed about 100 to 150 basis points to that platform’s growth rate during the quarter. BD increased its U.S. advanced patient monitoring sales force by about 15%, Polen said. The company also expanded investments in the Veterans Affairs channel for PureWick and increased its U.S. peripheral intervention sales team by 15%. During the quarter, BD launched or expanded several products, including the Liverty TIPS Stent Graft in Europe, the Elyra Thulium Fiber Laser System for kidney stone procedures, and the Acumen IQ plus finger cuff and Smart Pressure Controller for its HemoSphere Alta monitoring platform. The Acumen technologies are commercially available in the U.S. and Europe, according to the company. Adjusted gross margin was 54.3% and adjusted operating margin was 24.9%, down 100 basis points and 130 basis points, respectively, from the prior year. Productivity gains and favorable mix were offset by approximately 110 basis points of tariff impact, as well as continued investment in selling and research and development activities. Polen said BD generated approximately 8% gross productivity in its plants during the quarter, supported by plant consolidations, raw-material savings, waste reduction and improved efficiency on critical production lines. Service levels exceeded 90%, while back orders reached record lows, he said. Year-to-date free cash flow rose 45% from the prior year to $1.7 billion, reflecting improved working capital and lower non-operating cash items, including Alaris remediation outlays. BD returned $3.1 billion to shareholders year to date, including about $2.3 billion in share repurchases and $0.9 billion in dividends. Net leverage ended the quarter at about 2.9 times, compared with the company’s long-term target of 2.5 times. BD now expects fiscal 2026 revenue growth toward the high end of its low-single-digit FX-neutral range. Based on current spot rates, the company expects foreign exchange to provide approximately a 100-basis-point tailwind to reported revenue. It continues to expect adjusted operating margin of about 25%, including tariff effects, and an adjusted effective tax rate between 16% and 17%. Looking ahead to fiscal 2027, Roque said BD continues to view low-single-digit revenue growth as a reasonable starting framework because the end of Alaris remediation is expected to create a 200-basis-point revenue headwind. He said the company expects “modest” earnings leverage from that revenue baseline, supported by pricing actions, BD Excellence productivity measures and capital allocation actions. Polen said vaccine pressure in China appeared to be stabilizing and that BD expects to begin lapping the vaccine headwind in the next quarter. China represented about 4% of New BD revenue and could decline into the 3% range as other parts of the company grow faster, he said. BD also announced that Mike Garrison, executive vice president and president of the Medical Essentials and BioPharma Systems segments, intends to retire after more than 20 years with the company. Peter Menziuso joined BD on June 1 as executive vice president and president of BD Interventional. Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies. BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Becton, Dickinson and Company Q3 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

Becton, Dickinson and Company BDX, popularly known as BD, delivered adjusted earnings per share (EPS) of $3.23 in the third quarter of fiscal 2026, up 4.9% year over year. The figure topped the Zacks Consensus Estimate by 2.9%. The adjustments include expenses related to purchase accounting adjustments and restructuring costs, among others. GAAP EPS for the quarter was $1.64, up 4.5% year over year. BD registered revenues of $4.98 billion in the fiscal third quarter, up 5.4% year over year on a reported basis. The figure surpassed the Zacks Consensus Estimate by 1.8%. At constant exchange rate (CER), revenues climbed 4.4% year over year. Robust performances by all the segments drove the top-line improvement. Shares of this company gained nearly 1.8% in today’s pre-market trading. Effective Oct. 1, 2025, BD reorganized its organizational units into five distinct, separately-managed segments, which are based on the nature of its product and service offerings. However, subsequent to the spin-off of BDX's former Biosciences and Diagnostic Solutions business and the combination of the business with Waters, the Life Sciences segment was eliminated, leaving the company with four distinct, separately-managed segments. In the quarter under review, the Medical Essentials segment reported revenues of $1.68 billion, up 4.5% and 3.2% from the year-ago quarter on a reported basis and at CER, respectively. Revenues in the Connected Care segment totaled $1.22 billion, up 4.9% year over year on a reported basis and 4.4% at CER. BioPharma Systems segment generated revenues of $670 million, up 6.6% year over year on a reported basis and 5.2% at CER. BD Interventional segment generated revenues of $1.41 billion, up 6.4% from the year-ago quarter on a reported basis and 5.5% at CER. In the third quarter of fiscal 2026, revenues in the United States improved 6.9% year over year to $3.08 billion. International revenues grossed $1.90 billion, up 3.2% from the year-ago quarter on a reported basis and 0.6% at CER. Becton, Dickinson and Company price-consensus-eps-surprise-chart | Becton, Dickinson and Company Quote In the quarter under review, BD’s gross profit increased 3.6% year over year to $2.32 billion. However, the gross margin contracted 83 basis points (bps) to 46.5%. Selling and administrative expenses increased 8.4% year over year to $1.26 billion. Research and development expenses increased 12.2% year over year to $258 million. Adjusted operating expenses of $1.52 billion rose 9% year over year. Adjusted operating profit totaled $796 million, reflecting a 5.5% decrease from the year-ago quarter. The adjusted operating margin in the fiscal third quarter contracted 184 bps to 15.9%. BD exited third-quarter fiscal 2026 with cash and cash equivalents and short-term investments of $709 million compared with $816 million at the fiscal second-quarter end. Total debt (including current debt obligations) at the end of the fiscal third quarter was $16.81 billion compared with $17.28 billion at the fiscal second-quarter end. Cumulative net cash provided by continuing operating activities at the end of third-quarter fiscal 2026 was $2.10 billion compared with $1.58 billion a year ago. Meanwhile, BD has a consistent dividend-paying history, with its five-year annualized dividend growth being 5.32%. BD has revised guidance for fiscal 2026 for New BD. BD continues to project its full fiscal year revenues to grow above low single-digit on a reported basis, while it continues to expect them to grow at low single-digit at CER. For the full fiscal year, adjusted EPS is now anticipated to be in the range of $12.62-$12.72, narrowed from the prior outlook of $12.52-$12.72. The Zacks Consensus Estimate is pegged at $12.53. BD exited the third quarter of fiscal 2026 with better-than-expected results and solid top- and bottom-line results. Robust performances by all segments and both geographic regions were encouraging. Apart from these, there were a few other developments during the recent period. BDX was awarded a Vizient Innovative Technology contract for the BD CentroVena One Insertion System. The company launched the Elyra Thulium Fiber Laser System, thus expanding its kidney stone care portfolio. BD also announced a collaboration with Brazil-based pharmaceutical company, EMS, to expand access to GLP-1 therapies through a semaglutide launch utilizing BD's Vystra Injection Pen platform to support consistent, reliable self-injection for patients with obesity and type 2 diabetes. These raise our optimism about the stock. However, the contraction of both margins does not bode well. BDX currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space that have announced quarterly results are BrightSpring Health Services, Inc. BTSG, Quest Diagnostics Incorporated DGX and Avantor, Inc. AVTR. BrightSpring, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2026 adjusted EPS of 45 cents, beating the Zacks Consensus Estimate by 21.6%. Revenues of $3.87 billion outpaced the consensus mark by 6.1%. You can see the complete list of today’s Zacks #1 Rank stocks here. BrightSpring has a long-term estimated growth rate of 46%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 16.1%. Quest Diagnostics reported second-quarter 2026 adjusted EPS of $3.12, beating the Zacks Consensus Estimate by 11%. Revenues of $3.04 billion surpassed the Zacks Consensus Estimate by 2.2%. It currently carries a Zacks Rank #2 (Buy). Quest Diagnostics has a long-term estimated growth rate of 9.7%. DGX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%. Avantor reported second-quarter 2026 adjusted EPS of 21 cents, beating the Zacks Consensus Estimate by 10.5%. Revenues of $1.69 billion surpassed the Zacks Consensus Estimate by 4.2%. It currently carries a Zacks Rank #2. Avantor has a long-term estimated growth rate of 1.6%. AVTR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 4.3%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Avantor, Inc. (AVTR) : Free Stock Analysis Report BrightSpring Health Services, Inc. (BTSG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

For the quarter ended June 2026, Becton Dickinson (BDX) reported revenue of $4.98 billion, down 9.6% over the same period last year. EPS came in at $3.23, compared to $3.68 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $4.89 billion, representing a surprise of +1.81%. The company delivered an EPS surprise of +2.87%, with the consensus EPS estimate being $3.14. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Becton Dickinson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Connected Care- Medication Management Solutions- International: $178 million versus the two-analyst average estimate of $178.72 million. The reported number represents a year-over-year change of -0.6%. Revenues- Interventional- Surgery- International: $116 million versus $111.26 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +14.9% change. Revenues- Interventional- United States: $957 million compared to the $947.23 million average estimate based on two analysts. The reported number represents a change of +6.6% year over year. Revenues- Connected Care- Medication Management Solutions- United States: $737 million compared to the $711.11 million average estimate based on two analysts. The reported number represents a change of +4% year over year. Revenues- Interventional: $1.41 billion versus the three-analyst average estimate of $1.39 billion. The reported number represents a year-over-year change of +6.5%. Revenues- Interventional- Surgery: $422 million versus the three-analyst average estimate of $417.5 million. The reported number represents a year-over-year change of +6.8%. Revenues- Interventional- Peripheral Intervention: $552 million versus $528.5 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7.8% change. Revenues- Interventional- Urology and Critical Care: $440 million versus $447.64 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4.3% change. Revenues- Medical Essentials- Medication Delivery Solutions: $1.16 billion compared to the $1.17 billion average estimate based on three analysts. Revenues- Connected Care- Medication Management Solutions: $915 million versus $896.89 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +3% change. Revenues- Connected Care: $1.22 billion compared to the $1.2 billion average estimate based on three analysts. Revenues- Connected Care- Advanced Patient Monitoring: $309 million compared to the $301.13 million average estimate based on three analysts. View all Key Company Metrics for Becton Dickinson here>>> Shares of Becton Dickinson have returned +13.4% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Performance was driven by the 'New BD' focused portfolio, with over 90% of the business delivering high single-digit growth through commercial momentum and product innovation. Management attributed strong U.S. results in Medical Delivery Solutions (MDS) to broad underlying utilization and share gains across the Vascular Access Management portfolio. The 'Compete' strategy is accelerating growth through targeted commercial investments, contributing approximately 100 to 150 basis points to Advanced Patient Monitoring (APM) growth. BioPharma Systems momentum is fueled by high win rates in the biologics market, specifically securing approximately 100 agreements across novel and biosimilar GLP-1 programs. Operational execution via 'BD Excellence' delivered 8% gross productivity in plants, maintaining service levels above 90% despite a dynamic macro environment. Strategic pivots in innovation are focusing R&D on high-growth sectors like connected care, automation, and chronic disease treatment to enhance long-term mix. Fiscal 2027 revenue is characterized as low single-digit growth due to a 200 basis point headwind as the Alaris remediation period concludes. Management assumes a 'modest leverage' framework for fiscal 2027 earnings, supported by pricing actions, productivity gains, and favorable product mix. The company is deploying a standardized digital platform to run AI across the end-to-end supply chain, targeting future productivity and inventory improvements. Guidance assumes continued stabilization in the China market, which now represents approximately 4% of the 'New BD' revenue base. Capital allocation remains focused on high-growth tuck-in M&A and achieving a 90% free cash flow conversion target over time. Margins were impacted by approximately 110 basis points of tariff headwinds during the quarter, partially offset by productivity gains. The Alaris capital comparison created a 100 basis point headwind in Q3, which is expected to increase to a 200 basis point headwind in Q4. Management noted continued pressure in the China vaccines market, though they anticipate starting to lap this headwind in the coming quarter. Input cost assumptions include sensitivity to oil prices; management estimated a $60 million to $70 million COGS impact if oil stays above $100. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Growth is driven by 4 platforms growing double digits and others at high single digits, reflecting a purposeful shift into faster-growing markets. Management expects these platforms to continue fueling gross margin expansion through favorable product mix. BD appointed its first Chief Revenue Officer to standardize commercial excellence and is deploying AI tools to assist sales teams in account targeting. Incremental investments, such as a 15% increase in the Peripheral Intervention (PI) sales team, are translating into consecutive quarters of acceleration. Utilization remains solid across ubiquitous products like catheters and syringes, which serve as bellwether indicators for general health care consumption. Management observed an uptick in the ratio of tubes to needles, suggesting more diagnostic testing is being performed per patient collection. Vaccine headwinds are showing signs of stabilization, and management does not currently expect a repeat of this year's headwind level in fiscal 2027. China's impact is diminishing as it becomes a smaller portion (approximately 4%) of the total 'New BD' revenue portfolio.

Becton Dickinson (BDX) came out with quarterly earnings of $3.23 per share, beating the Zacks Consensus Estimate of $3.14 per share. This compares to earnings of $3.68 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +2.87%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $2.77 per share when it actually produced earnings of $2.9, delivering a surprise of +4.69%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Becton Dickinson, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $4.98 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.81%. This compares to year-ago revenues of $5.51 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Becton Dickinson shares have lost about 12.1% since the beginning of the year versus the S&P 500's gain of 12.8%. While Becton Dickinson has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Becton Dickinson was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $4.11 on $5.13 billion in revenues for the coming quarter and $12.53 on $19.34 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 15% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Staar Surgical (STAA), has yet to report results for the quarter ended June 2026. The results are expected to be released on August 12. This maker of implantable lenses is expected to post quarterly earnings of $0.21 per share in its upcoming report, which represents a year-over-year change of +400%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Staar Surgical's revenues are expected to be $90.77 million, up 104.8% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report STAAR Surgical Company (STAA) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research